… Recent innovations in prostate cancer diagnosis include new … base on cost-effectiveness of
these developments (eg, Prostate … areas of improvement for future cost-effectiveness models. …

… effects and cost-effectiveness of PSA screening with S3M used as a reflex test above a PSA
of 1, 1.5 or 2 ng/mL compared with no prostate cancer screening or PSA screening alone. …

Background Standard biopsy for prostate cancer diagnosis is an unpleasant and sometimes
painful procedure with a detection rate as low as around 50%. Consequently, an accurate …

… Of the seven cost-effectiveness analyses, effectiveness outcomes were modelled based on
… ], although for that study the effectiveness outcome was not QALYs but the number of missed …

… in prostate cancer cells compared to non-cancerous prostate tissue. The PCA3 score is
calculated using the Progensa … QALY with an incremental cost-effectiveness ratio of 58,404 USD …

… main studies evaluating the utility and cost effectiveness of prostate cancer biomarkers.
Table 2 shows the design and limitations of studies investigating prostate cancer biomarkers. …

… According to the EAU guidelines, this test is mainly indicated as an aid to guide the decision
of repeat biopsy after a first negative biopsy, although its clinical effectiveness for this goal is …

… However, the cost-effectiveness decisions about a … cancers. This study also provides a
general economic evaluation framework to analyze the cost-effectiveness of any novel marker to …

… January 2000 and October 2020 to report the available parameters and cost-effectiveness
of the aforementioned diagnostic tests. We focus on the … Comparative effectiveness of tests …

… than in benign prostatic hyperplasia. The test was FDA-approved in 2012. The Progensa PCA3
… Commercially available Progensa PCA3 urine test outweighs the total and percentage of …